33 reports

  • Genetic Disorders
  • PANCREATIC CANCER THERAPEUTICS, EFFICACY AND SAFETY RESULTS FOR KEY PARAMETERS - PIPELINE AND MARKETED PRODUCTS (LIGHT
  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • Celgene Corporation

Pancreatic cancer

4546 5000 3864
  • HYPERACUTE-PANCREAS DRUG PROFILE
  • PRODUCT PROFILE (LATE STAGE): HYPERACUTE-PANCREAS

THERE ARE A RANGE OF INHERITED GENETIC SYNDROMES IMPLICATED IN INCREASED PANCREATIC CANCER RISK A number of inherited genetic syndromes and/ or gene mutations have been implicated in an increased risk of developing pancreatic cancer.

  • Pancreatic Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.

The intersection of artificial intelligence with genetic treatments for cancer represents a significant market opportunity.

  • Pancreatic Cancer
  • United States
  • World
  • Market Size
  • GE Healthcare Limited
  • VARIATION BY GEOGRAPHY/ETHNICITY

Differences in geographic occurrence of the cancer suggest a possible genetic link to the underlying cause.

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Europe

The drug candidate is developed based on Genetically Modified Fly technology.

  • Pancreatic Cancer
  • Research And Development
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients

The company primarily focuses on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease.

  • Healthcare
  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • GlobalData's company

WHIM is a genetic primary immunodeficiency disease caused by the abberant trafficking of specific immune cells that are critical for proper immune system functions.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

Erytech Pharma SA (ERYP) Pharmaceuticals & Healthcare - Deals and Alliances Profile October 2017 Report Code: GDPH##D Published: Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that offers development of therapies for rare forms of cancer and orphan diseases.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Company
  • Erytech Pharma SA
  • 02/26/2016: PHARMACYTE BIOTECH PANCREATIC CANCER TREATMENT TO TARGET RECENTLY IDENTIFIED FORMS OF PANCREATIC CANCER
  • OCT 24, 2016: PHARMACYTE BIOTECH SELECTS DR. MANUEL HIDALGO AS PRINCIPAL INVESTIGATOR FOR ITS PANCREATIC CANCER CLINICAL TRIAL

The gene may then be inserted or " transfected" into the genetic code of live human cells.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Company
  • PharmaCyte Biotech, Inc.
  • ITALY PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET,
  • 6.3 BY GEOGRAPHY

Even though in the majority of high-risk individuals a genetic test to identify familial predisposition is not available, a screening protocol seems to be reasonable for subjects who have a > ##-fold greater risk for the development of PDAC.

  • Cancer
  • Diagnostics
  • Pancreatic Cancer
  • Market Size
  • Beckman Coulter, Inc.

In theory, Ampligen induced crossprotection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Biopharmaceutical
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT DESCRIPTION
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT STATUS

CLINICAL GENETIC TEST VOLUME(##) GREW ##% DRIVEN BY THE INCLUSION OF CLARIENT' S RESULTS IN THE CONSOLIDATED TOTAL.

  • Clinical Trial
  • Immunochemistry Test
  • Pancreatic Cancer
  • United States
  • GlobalData's company
  • PANCREATIC CANCER - PIPELINE BY ACLARIS THERAPEUTICS INC, H2 2017
  • ONCOLYTIC VIRUS TO TARGET CPEB4 FOR PANCREATIC CANCER - DRUG PROFILE

Responses were observed across multiple genetic subtypes of AML.

  • Pancreatic Cancer
  • Pharmaceutical
  • North America
  • United States
  • Product Initiative
  • PANCREATIC CANCER - PIPELINE BY CONFLUENCE LIFE SCIENCES INC, H1 2017
  • CELLULAR IMMUNOTHERAPY TO TARGET KRAS FOR ONCOLOGY - DRUG PROFILE

IT IS DEVELOPED BASED ON GENETIC ANALYSIS TECHNOLOGY PLATFORM.

  • Cancer
  • Pancreatic Cancer
  • North America
  • United States
  • Product Initiative

The poster entitled ' PIM## Inhibitor as a Targeted Therapy for the Treatment of Multiple Myeloma Patients with Specific Genetic Signatures', will be presented on April ##, 2013.

  • Cancer
  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Product Initiative
  • Clinical Trial profile. 2315 Trial Title
  • 5. All the trials included are unique trials.

The researchers analyzed genetic, tumor micro-environmental, and immunologic factors in tumors derived from a transgenic model of breast cancer.

  • Cancer
  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • World
  • MDX - PANCREATIC CANCER - PRODUCT STATUS
  • MDX - PANCREATIC CANCER - PRODUCT DESCRIPTION
  • Molecular Diagnostic
  • Pancreatic Cancer
  • Sexually Transmitted Disease
  • United States
  • Seegene, Inc.
  • Biopharmaceutical
  • Cancer
  • Pancreatic Cancer
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • NECUPARANIB - DRUG PROFILE
  • CELLULAR IMMUNOTHERAPY TO TARGET GM-CSFR FOR PANCREATIC CANCER - DRUG PROFILE

The clinical responses have been independent of high-risk clinical or genetic features.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

NA : Not Available Source: Global Markets Direct harbor a specific genetic lesion in the gene Neurofibromatosis Type ## (NF##), which results in the loss of the protein Merlin and increased sensitivity to FAK inhibition.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • Verastem, Inc.

M## extended survival of a genetically engineered mouse model for pancreatic cancer when it was combined with the current standard of care chemotherapy gemcitabine.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Product Initiative
  • Juventas Therapeutics, Inc.
  • Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Featured News & Press Releases

M## extended survival of a genetically engineered mouse model for pancreatic cancer when it was combined with the current standard of care chemotherapy gemcitabine.

  • Pancreatic Cancer
  • Therapy
  • World
  • Product Initiative
  • Progen Pharmaceuticals Limited
  • COURTAGEN LIFE SCIENCES, INC. PIPELINE PRODUCTS SUMMARY BY DEVELOPMENT STAGE DEVELOPMENTAL STAGE

" There are a large number of patients who suffer from non-genetic forms of epilepsy or seizures, or may not need a genetic diagnosis, but who are being treated with anticonvulsants.

  • Breast Cancer
  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Courtagen Life Sciences, Inc.

" We are excited by the findings of this study, and are already pursuing some of the new leads that emerge from it, " said Yetrib Hathout, Associate Professor in the Department of Integrative Systems Biology, Center for Genetic Medicine at Children' s National Health System and

  • Mental Health
  • Pancreatic Cancer
  • Pathology
  • United States
  • SomaLogic, Inc.

Genetic Conditions Leading to Pancreatic Cancer ## ##. ##. ## Conclusion ## ##. ## Pathophysiology ## ##. ##. ## Frequently Dysregulated Pathways ## ##. ##. ## Oncogenes ## ##. ##. ## Tumor Suppressor Genes ## ##. ## Diagnosis ## ##. ## Prognosis ## ##. ## Treatment Options ## ##. ##. ## Surgery ## ##. ##. ## Radiation therapy ## ##

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • DORMANT PROJECTS (CONTD..4), H2 2016

genetic defects from EU Community register.

  • Chemotherapy
  • Hospital
  • Pancreatic Cancer
  • United States
  • Product Initiative

Sickle cell disease is one of the most prevalent genetic disorders in the U. S.

  • Blood Supply
  • Pancreatic Cancer
  • United States
  • World
  • Product Initiative
  • CHARIS-1000 - DRUG PROFILE
  • CELLULAR IMMUNOTHERAPY TO TARGET GM-CSFR FOR PANCREATIC CANCER - DRUG PROFILE

The clinical responses have been independent of high-risk clinical or genetic features.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

In June 2006, Insmed Incorporated Limited has withdrawn orphan drug designation for mecasermin rinfabate for the treatment of growth hormone deficiency and primary insulin-like growth factor-## deficiency due to molecular or genetic defects.

  • Lung Cancer
  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • Product Initiative

Genetic Resistance". ##-May-2014 Cell Therapeutics, Inc. has announced that it will change its corporate name to CTI BioPharma Corp. and the change of the company' s name will entail with effective from May ##, 2014.

  • Lung Cancer
  • Pancreatic Cancer
  • United States
  • World
  • Product Initiative